Compare ASTL & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTL | MYGN |
|---|---|---|
| Founded | 1902 | 1991 |
| Country | Canada | United States |
| Employees | N/A | 2700 |
| Industry | Steel/Iron Ore | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 481.6M |
| IPO Year | N/A | 1996 |
| Metric | ASTL | MYGN |
|---|---|---|
| Price | $4.38 | $5.14 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.06 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | N/A | $7.19 |
| Revenue Next Year | N/A | $5.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $3.02 | $3.76 |
| 52 Week High | $7.25 | $11.44 |
| Indicator | ASTL | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.21 | 51.59 |
| Support Level | $4.14 | $4.82 |
| Resistance Level | $4.64 | $5.67 |
| Average True Range (ATR) | 0.28 | 0.39 |
| MACD | -0.04 | 0.13 |
| Stochastic Oscillator | 12.58 | 64.60 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.